Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty

Kaleb Michaud1,2,3, Edward V Fehringer3, Kevin Garvin3, James R O’Dell1,3 and Ted R Mikuls1,3,4*

Abstract

Introduction: Serious infection, cardiovascular disease, and mortality are increased in rheumatoid arthritis (RA). Whether RA affects the risk for these complications after total joint arthroplasty (TJA) is unknown, we hypothesize that it does. We compared the occurrence of 30-day postoperative complications and mortality in a large cohort of RA and osteoarthritis (OA) patients undergoing hip or knee TJA.

Methods: Analyses included 7-year data from the Veterans Affairs Surgical Quality Improvement Program. The 30-day complications were compared by diagnosis by using logistic regression, and long-term mortality was examined by using Cox proportional hazards regression. All analyses were adjusted for age, sex, and clustering by surgical site. Additional covariates included sociodemographics, comorbidities, health behaviors, and operative risk factors.

Results: The 34,524 patients (839 RA, 33,685 OA) underwent knee (65.9%) or hip TJA. Patients were 95.7% men with a mean (SD) age of 64.4 (10.7) years and had 3,764 deaths over a mean follow-up of 3.7 (2.3) years. Compared with OA patients, those with RA were significantly more likely to require a return to the operating room (odds ratio (OR), 1.45 (95% CI, 1.08 to 1.94), but had similar rates of 30-day postoperative infection, OR 1.02 (0.72 to 1.47), cardiovascular events, OR 0.69 (0.37 to 1.28), and mortality, OR 0.94 (0.38 to 2.33). RA was associated with a significantly higher long-term mortality; hazard ratio (HR), 1.22 (1.00 to 1.49).

Conclusion: In this study of US veterans, RA patients were not at an increased risk for short-term mortality or other major complications after TJA, although they returned to the operating room more often and had increased long-term mortality.

Introduction

Total joint arthroplasty (TJA) is among the most commonly performed elective surgeries, with more than a million total knee and hip arthroplasties completed in the United States in 2010 alone [1]. Overall charges in the United States for knee TJA in 2005 were US$8.85 billion [2,3]. With a rapidly aging population, coupled with increasing arthritis prevalence [4] and an escalation in the use of TJA [5-7], these numbers are expected to grow exponentially over the next few decades. Numerous investigations have detailed the substantial benefit of TJA in the treatment of end-stage arthropathy, benefits that include significant pain relief and improved functional status. Whereas general acceptance exists regarding the efficacy of TJA in end-stage arthritis, significant controversy surrounds the selection of patients who are most likely to benefit from joint-replacement surgery and, conversely, which patients are most likely to experience serious postoperative complications. Specifically, limited studies have examined the impact of TJA on overall mortality [8-15].

In addition to a focus on important clinical improvements in pain and function, most studies examining arthroplasty outcomes have exclusively involved patients with osteoarthritis (OA) because of its greater prevalence. The underrepresentation of patients with other forms of arthritis is highly relevant because TJA has been widely adopted as a therapeutic approach in other conditions, including rheumatoid arthritis (RA). Estimates suggest that approximately 18% to 25% of RA...
patients undergo TJA from disease onset more than 20 years [16,17]. RA patients have a higher prevalence than non-RA patients of selected comorbidities (that is, cardiovascular disease and serious infection) that could render this population at higher risk for serious postoperative complications after TJA. A recent systematic review of complications after TJA in RA and OA highlighted the need for more studies investigating these differences, most notably in infections, as their study hinted at increased risks in RA and mortality, for which most studies were underpowered [18].

In the present study, we assessed 30-day postoperative status, including cardiovascular events and infections, for a large population of patients with RA and OA undergoing initial TJA of the knee and hip. With a paucity of previous studies examining outcomes after TJA in RA, we also sought to identify patient factors associated with worse outcomes in this at-risk population.

Methods

Study subjects

Study subjects included patients in the Veterans Affairs Surgical Quality Improvement Program (VASQIP) database from years 1999 through 2006. VASQIP is a validated prospective quality-assurance and data-collection program that includes comprehensive data from surgeries performed under either general or epidural anesthesia [19,20]. An assessment of VASQIP has shown the data-collection efforts to be highly reliable, with >73% of data elements having substantial or almost perfect agreement with other surgical datasets [21]. As previously described, the database includes data on preoperative risk variables, intraoperative variables, and postoperative outcomes, including all-cause mortality [22]. The present study included surgical data from 106 collection sites from patients undergoing their first TJA of the hip or knee during the observation period. Total hip and knee arthroplasties were defined by using Current Procedural Terminology (CPT) codes of 27310 and 27447, respectively. Patients undergoing emergency surgery were excluded.

The VASQIP database was linked to outpatient and inpatient pharmacy dispensing data from the VA Pharmacy Benefits Management (PBM) database for the 1-year period preceding the index surgery. Linked PBM data also included all inpatient and outpatient ICD9 diagnoses for 1 year preceding surgery. Patients were classified as having RA if they had (a) at least one diagnostic code for RA (714.0) and (b) use of at least one biologic or nonbiologic DMARD during the 1-year preoperative period. This definition has previously been shown to have sensitivity/specificity exceeding 80% for identifying patients with RA [23]. Patients were categorized as having OA if they had at least one diagnostic code for OA (715.0 to 715.9), received no DMARDs 1 year before surgery, and lacked ICD9 codes for RA or alternative inflammatory arthritides (099.3, 555.9, 696.0, 710.0, 711.1*, 714.*, and 720.*). Patients who met only one of the two requirements for RA diagnosis, irrespective of OA diagnosis, were excluded from primary analysis. The Institutional Review Board and the Research & Development Committee at the Omaha VA Medical Center, in addition to the VASQIP Executive Committee, approved this protocol.

Postoperative status and outcomes

Primary outcomes for the study were simplified into one continuous and several dichotomous variables: postoperative stay at hospital in days; return to the operating room; any complications [20]; any cardiovascular complications (cardiac arrest requiring CPR, myocardial infarction, cerebrovascular accident, pulmonary embolism, or deep-vein thrombosis); any infection complications (systemic sepsis, pneumonia, urinary tract infection, superficial surgical-site infection, and deep wound surgical-site infection); and mortality status.

Personnel in the VASQIP Data Center determined vital status by cross-matching these data with veteran death records in the Beneficiary Identification of Records Locator System (BIRLS) of the Veterans Benefits Administration. This system identifies all deaths, regardless of cause, affecting VA beneficiaries [21]. We defined short-term mortality status as mortality within 30 days of surgery. We obtained date of death through December 31, 2006.

Predictors of postoperative outcomes

In addition to the specific type of TJA and arthritis diagnosis (RA versus OA), several potential determinants of postoperative outcomes included both preoperative and intraoperative factors [21]. Preoperative factors examined included age, gender, race, smoking status, diabetes mellitus, alcohol use, chronic obstructive pulmonary disease (COPD), patient-reported dyspnea, congestive heart failure (CHF), cerebrovascular disease, chronic glucocorticoid use, American Society of Anesthesiologists (ASA) class (dichotomized as healthy/mild versus severe/very severe), functional health status rated by dependency, and inclusive calendar 2-year of procedure categorized as 1999 through 2000, 2001 through 2002, 2003 through 2004, and 2005 through 2006.

Additional preoperative risk factors examined included seven selected laboratory abnormalities: blood urea nitrogen >40 mg/dl, creatinine >1.2 mg/dl, hematocrit ≤38%, platelet count ≤150,000/μl, serum sodium ≤135 or >145 mM, or white blood cell count >11,000/μl.

Intraoperative factors examined included total operative time and anesthesia type. Potential predictor variables that were missing for more than 15% of patients were excluded (for example, do-not-resuscitate status,
were found in smoking status. RA patients were less likely to consume alcohol. No significant differences existed between RA and OA.

Although VASQIP records if the patient is taking glucocorticosteroids (GCSs) before surgery, we thought greater understanding of the patient’s GCS history could be important for surgical outcomes. By using the VA PBM, we identified patients that were dispensed the GCSs dexamethasone, hydrocortisone, prednisolone, prednisone, or methylprednisolone at 30 days, 6 months, and 1 year before TJA surgery. We also identified patients who were dispensed GCS 10 days before surgery to account for possible perioperative stress dosing.

Statistical analysis
Descriptive and comparative analysis was conducted by using the t test for continuous measures and a test of difference between two proportions for dichotomous measures. We conducted multivariable logistic and linear regressions with backward stepwise selection for analyzing each outcome of interest, with age, sex, and TJR type kept in every model. All regressions clustered patients by surgical site.

Short-term mortality analysis used a similar model with multivariable logistic regression of mortality status at 30, 180, or 365 days after surgery. Longitudinal mortality analysis was conducted by using Cox proportional hazards regression models, with the surgery date as the initial date for mortality risk until the date or death or censorship at December 31, 2006.

Data were analyzed by using Stata (College Station, TX, USA) version 11.1. Statistical significance was set at the 0.05 level; confidence intervals were established at 95%; and all tests were two-tailed.

Results

Patient characteristics
Of the 34,524 patients included in our primary analysis, only 839 (2.4%) had a qualifying RA diagnosis, with the remaining 33,685 (97.6%) having OA. Most surgeries were total knee arthroplasties (TKAs) (65.9%), and the average (SD) length of stay was 7.7 (7.3) days. Table 1 shows the characteristics of the patients by diagnosis. In comparison with OA patients, RA patients were younger, more likely to be female and Caucasian, and less likely to consume alcohol. No significant differences were found in smoking status. RA patients were less likely to have diabetes mellitus, although they were more likely to be rated with poor functional health.

Several DMARDs were taken by RA patients before surgery, including methotrexate (58.6%), hydroxychloroquine (40.4%), biologics (24.0%), and sulfasalazine (23.2%). By definition of diagnosis group, none of the OA patients was taking a DMARD. RA patients were much more likely to be taking GCS and chemotherapy and less likely to be taking low-dose aspirin before surgery (Table 1).

A large number of patients were missing several preoperative laboratory measures, with only 10,673 patients (10,387 OA and 286 RA) having all 13 values available (Additional file 1: Table S1). This group was studied in a separate analysis that included all laboratory values, as abnormalities may have been associated with other comorbidities or alerted the surgeon to take precautionary measures. Of the preoperative laboratory values used in the primary analysis, 7.3% of patients were missing at least one of the seven values examined.

TJA complications
We examined the association of all covariates on several surgical-complication outcomes (Table 2) in multivariable regressions. A post-operative cardiovascular event occurred in 2.0% of patients, and although it was associated with risk factors such as age, time of operation, COPD, dyspnea, preoperative wound or infection, transient ischemic attack (TIA) history, and creatinine >1.2 mg/dl clearance, factors including male sex and RA versus OA were not significantly associated (Table 3). Even more covariates were linked with postoperative infections, including the receipt of diabetes treatments, female sex, and poor functional health, although again, RA diagnosis had no association and, unexpectedly, GCS dispensing in the month before TJA was protective (OR, 0.75 (95% CI, 0.58 to 0.96)). Deep-wound surgical infections had similar associations, although a positive association was noted with dispensing in the 6 months before surgery (OR, 1.86 (1.33 to 2.60)). Considering all post-TJR complications, neither an association with RA diagnosis nor one with the specific target joint being replaced was found, as shown in Table 3.

In similar analysis, length of hospital stay in days during TJA was increased by a day for each decade of age, another day for each hour of surgery, and a half-day for having hip (versus knee) surgery, and was decreased a day for men and for every 3 calendar years. No association was found between having RA with this length of hospital stay, although having CHF, stroke, diabetes, COPD, GCS use in the past year, and poor functional status were all associated with an increased length of stay. When looking at any return to the operating room within 30 days of TJA, RA patients were 40% more likely
to return to the operating room (OR, 1.41 (1.05 to 1.90)), as were those receiving hip versus knee surgery (OR, 1.38 (1.17 to 1.63)). No analyses showed an association of removing or separating patients who had GCS use within 10 days before surgery from those patients who took GCS in larger time windows beforehand.

We repeated these analyses for the subset of 10,673 patients with full laboratory data. Except for the length of stay, for which RA patients had a significantly decreased stay of −0.97 (−1.82 to −0.12) days, none of the other TJA outcomes had appreciable differences in magnitude between RA and OA.

**TJA mortality**

In total, 3,764 deaths over a mean follow-up of 3.7 (2.3) years occurred in the analysis cohort. Mortality was initially examined in models similar to other complications, although at three discrete time points after TJA. At no point up to 1 year was there a statistically important difference between RA and OA, although after covariate

---

**Table 1 Characteristics of VA VASQIP patients receiving TKA or THA by OA or RA diagnosis**

|                      | OA (n = 33,685) |          | RA (n = 839) |          | P value |
|----------------------|-----------------|----------|--------------|----------|---------|
|                      | Missing Mean SD |          | Missing Mean SD |          |         |
| **Demographics and comorbidity** |                  |          |               |          |         |
| Age (years)          | 0 64.49 10.72   | 0 62.19 10.55 | <0.001       |         |
| Male sex (%)         | 0 95.73         | 0 93.09   | <0.001       |         |
| Caucasian (%)        | 2,236 72.73     | 49 76.08  | 0.037        |         |
| Alcohol consumption (%) | 348 7.66   | 6 4.08    | <0.001       |         |
| Current smoker (%)   | 204 24.23       | 3 22.85   | 0.356        |         |
| Diabetes mellitus (%)| 204 16.88       | 3 12.20   | <0.001       |         |
| COPD (%)             | 1 9.67          | 1 10.74   | 0.301        |         |
| Operation time (hours) | 1 2.26 0.76 | 0 2.29 0.77 | 0.248       |         |
| Low-dose aspirin (%) | 0 38.09         | 0 27.89   | <0.001       |         |
| Poor functional health (%) | 0 5.28 | 0 9.06    | <0.001       |         |
| Short of breath, dyspnea ≥2 (%) | 274 11.17 | 8 9.63    | 0.162        |         |
| General anesthesia (%) | 0 69.39     | 0 70.92   | 0.343        |         |
| Bleeding disorders (%) | 206 1.34      | 4 1.44    | 0.812        |         |
| Chemotherapy <30 days pre-op (%) | 206 0.22 | 5 3.60    | <0.001       |         |
| CHF <30 days pre-op (%) | 3 0.77       | 1 0.84    | 0.820        |         |
| TIA history (%)      | 211 2.18        | 4 2.04    | 0.773        |         |
| CVA/Stroke with neurologic deficit (%) | 209 2.02 | 4 1.44    | 0.234        |         |
| CVA/Stroke without neurologic deficit (%) | 209 2.29 | 4 2.75    | 0.375        |         |
| **GCS use before surgery** |                  |          |               |          |         |
| ≤30 days             | 0 5.70          | 0 49.94  | <0.001       |         |
| ≤0.5 year            | 0 11.68         | 0 62.22  | <0.001       |         |
| ≤1 year              | 0 16.03         | 0 67.70  | <0.001       |         |
| At surgery interview (VASQIP) | 0 1.16   | 0 41.12   | <0.001       |         |
| VASQIP or ≤1 year    | 0 16.42         | 0 69.25  | <0.001       |         |
| VASQIP and ≤1 year   | 0 0.77          | 0 39.45  | <0.001       |         |
| **Abnormal pre-op laboratory** |                |          |               |          |         |
| Hematocrit ≤38% (%)  | 693 15.43       | 13 30.51 | <0.001       |         |
| White blood cells >11,000/μl (%) | 890 3.85 | 16 10.45  | <0.001       |         |
| Platelets ≤150,000/μl (%) | 1,175 5.71 | 20 3.30   | 0.003        |         |
| Creatinine >1.2 mg/dl (%) | 1,533 31.33 | 34 23.85  | <0.001       |         |
| Serum sodium ≤135 mM (%) | 1,905 7.24 | 43 8.54   | 0.163        |         |
| Serum sodium >145 mM (%) | 1,905 1.63  | 43 1.01   | 0.165        |         |
| Blood urea nitrogen >40 mg/dl (%) | 2,990 0.93 | 80 0.79   | 0.689        |         |
adjustment, a trend was noted toward an increase in mortality for RA over time: 30-day OR 0.94 (0.38 to 2.33), 6-month OR, 1.25 (0.72 to 2.19), and 1-year OR, 1.30 (0.87 to 1.96).

When examining mortality over time continuously until 2007 by using Cox proportional hazards regression, RA patients had a hazard ratio (HR) of 1.22 (1.00 to 1.49). Associated covariates were similar to the prior dichotomous mortality analysis, and the full model is shown in Table 3. The Kaplan-Meier curve and adjusted survival function for this full model by diagnosis are shown in Figure 1.

**Discussion**

Covering 8 years in 106 VA surgical sites, our sizable study analyzed and compared the experiences of 34,524 OA and RA patients receiving their initial total knee- or hip-replacement surgery. No associations with RA versus OA were found for surgical complications, including cardiovascular and infectious events occurring within 30 days of the surgery. Whereas we found no association of RA with length of hospital stay, patients were significantly more likely to return to the operating room within 30 days of their TJA. Mortality remained similar for RA and OA after TJR, except for the increase in RA when we allowed a time horizon beyond 1 year after surgery.

Although our study is the second to use the VASQIP database to examine the impact of patient and surgery covariates on TKA and THA outcomes, the prior study by Weaver et al. [19] reported on data from 1991 to 1997, all before the current study’s start date of 1999, and did not have several of the measures we analyzed, including RA diagnosis. They did not find alcohol use to be significantly associated with postsurgical complications, in contrast with results from our study, which is consistent with a more recent analysis of VASQIP [24]. We previously analyzed a portion of the current data, comparing outcomes for total shoulder arthroplasty with TKA and THA, which provides an alternative view of the current study [25]. Both the study of Weaver et al. and our study complement each other and provide useful tools for determining the risk of postoperative complications by an individual patient’s characteristics, which is especially useful as the number of TJAs increases in the aging general and VA population.

Whereas the overall rates of TJA increase, the rates in RA patients have been decreasing in past decades, likely because of improvements in treatments, although TJA still represents an important outcome in the failure to control progressive joint damage from RA [8,16,26]. Although patients undergoing TJA have been reported to have a greater risk of surgical complications, our study did not find evidence of this. Whether orthopedic surgeons take greater preventative care when operating on RA patients or whether they postpone this often-elective procedure to a time (or indefinitely) with the least amount of RA activity, the current study’s observational data cannot address this, and we are left speculating.

A few studies have shown increased risk of TJA joint infection in RA versus OA patients [27,28], although all had a much longer follow-up in comparison to that of the current study, which found no statistically significant increased risk of 30-day infection in RA patients. Bongartz et al. [28] found 1.2% of 657 TJAs in RA had infection within 30 days, which is the same rate that we found for our superficial site infection, but much higher than our deep-wound site infection (0.4%). Although we also controlled for age, sex, function, comorbidities, prior infection, and more, we found no increase in RA infections; this difference may be because our population all had primary surgery, whereas they found most of their infections in TJA revision [28]. We did find contradictory results in the impact of GCS on overall

| Table 2 Surgical outcomes of patients receiving TKA or THA by OA or RA diagnosis |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                      | OA (n = 33,685) | RA (n = 839)    | P value         |
|                                      | Missing Mean SD | Missing Mean SD |                 |
| Outcome                              |                 |                 |                 |
| Postoperative stay (days)            | 130 7.77 7.31   | 7 7.77 5.79     | 0.994           |
| Return to operating room (%)         | 0 3.06 4.53     | 0 6.67 0.679    | 0.015           |
| Any complications (%)                | 0 7.04 0.67     | 0 1.31 0.139    | 0.679           |
| Any PO CV event (%)                  | 0 2.04 0.14     | 0 4.17 0.798    | 0.291           |
| Any PO infection (%)                 | 0 4.15 0.41     | 0 1.19 0.36     | 0.087           |
| Superficial surgical-site infection (%)| 0 1.10 0.65   | 0 0.36 0.291    |                 |
| Deep wound surgical-site infection (%)| 0 0.65 0.21    | 0 0.36 0.291    |                 |
| TJR type                             |                 |                 |                 |
| Hip (%)                              | 0 34.19 31.35   | 0 68.70 68.70   | 0.087           |
| Knee (%)                             | 0 65.80 68.70   | 0 68.70 68.70   | 0.087           |
Table 3 Multivariable logistic-regression model results for complications associated with hip or knee TJA

| Variable                                      | Any post-op cardiovascular event | Any post-op infection | Deep wound surgical-site infection | Any complications | Post-op stay (β in days) | Return to operating room within 30 days | Mortalityb |
|-----------------------------------------------|----------------------------------|-----------------------|-----------------------------------|-------------------|-------------------------|------------------------------------------|------------|
| RA versus OAc                               | 0.66 (0.35, 1.24)               | 1.14 (0.80, 1.62)     | 0.35 (0.12, 1.08)                 | 1.07 (0.80, 1.43) | −0.18 (~0.73, 0.38)      | 1.41 (1.05, 1.90)                         | 1.22 (1.00, 1.49) |
| Agec                                         | 1.03 (1.02, 1.04)               | 1.03 (1.02, 1.03)     | 0.99 (0.98, 1.01)                 | 1.02 (1.02, 1.03) | 0.10 (0.08, 0.12)        | 1.00 (0.99, 1.01)                         | 1.06 (1.05, 1.06)  |
| Male sexc                                     | 1.04 (0.66, 1.64)               | 0.68 (0.53, 0.87)     | 0.77 (0.46, 1.29)                 | 0.8 (0.67, 0.95)   | −1.06 (~1.51, -0.61)     | 1.05 (0.78, 1.42)                         | d          |
| Hip versus knee TJAc                        | 0.88 (0.73, 1.05)               | 1.10 (0.96, 1.26)     | 0.96 (0.68, 1.35)                 | 1.10 (0.99, 1.23)  | 0.62 (0.33, 0.90)        | 1.38 (1.17, 1.63)                         | 1.24 (1.16, 1.33) |
| Operation Time (in hours)                   | 1.10 (1.00, 1.22)               | 1.11 (1.01, 1.23)     | 1.22 (1.04, 1.43)                 | 1.16 (1.08, 1.24)  | 1.10 (0.75, 1.45)        | 1.23 (1.13, 1.33)                         | 1.30 (1.19, 1.41) |
| General anesthesia                          | 1.17 (1.00, 1.39)               | 1.43 (0.98, 2.10)     | 1.17 (1.04, 1.32)                 |                  |                        |                                          |             |
| Calendar year (1998–2006)                   | 1.03 (1.00, 1.07)               |                      |                                 |                  |                        | −0.28 (~0.37, -0.18)                     |             |
| Caucasian race                               |                                 |                      |                                 |                  |                        | −0.98 (~1.68, -0.28)                     |             |
| Alcohol consumption                          |                                 |                      |                                 |                  |                        |                                          |             |
| Current smoker                               | 0.78 (0.62, 1.00)               | 1.72 (1.30, 2.26)     |                                 |                  |                        |                                          |             |
| Poor functional health                       |                                 |                      |                                 |                  |                        |                                          |             |
| Short of breath, dyspnea ≥2                 | 1.53 (1.22, 1.93)               | 1.27 (1.10, 1.47)     |                                 |                  |                        |                                          |             |
| COPD history                                 | 1.27 (1.01, 1.60)               | 1.81 (1.52, 2.16)     |                                 |                  |                        |                                          |             |
| Bleeding disorder                           | 2.34 (1.63, 3.37)               | 1.83 (1.28, 2.62)     |                                 |                  |                        |                                          |             |
| Pre-op open wound/infection                 | 3.02 (1.28, 7.13)               | 2.46 (1.32, 4.60)     | 2.73 (1.62, 4.61)                 | 2.86 (1.53, 5.35)  | 1.91 (1.20, 3.04)        |                                          |             |
| TIA history                                  | 2.03 (1.46, 2.81)               | 1.41 (1.11, 1.79)     |                                 |                  |                        |                                          |             |
| Stroke history w/impairment                 |                                 |                      |                                 |                  |                        | 1.23 (1.09,1.38)                      |             |
| Stroke history w/o impairment               |                                 |                      |                                 |                  |                        | 1.57 (1.45,1.71)                      |             |
| CHF <30 days pre-op                         |                                 |                      |                                 |                  |                        | 1.53 (1.02,2.29)                      |             |
| Impaired sensorium                          |                                 |                      |                                 |                  |                        | 2.54 (0.61,4.47)                       |             |
| Diabetes: oral treatment                    | 1.18 (1.02, 1.37)               | 1.59 (1.14, 2.21)     |                                 | 1.2 (1.05, 1.37)  |                        |                                          |             |
| Diabetes: insulin treatment                 | 1.36 (1.09, 1.69)               | 2.48 (1.65, 3.73)     |                                 | 1.41 (1.18, 1.70) |                        |                                          |             |
| Diabetes: oral or insulin                   |                                 |                      |                                 |                  |                        | 0.40 (0.16, 0.64)                      |             |
| Chemotherapy <30 days preop                 |                                 |                      |                                 |                  |                        | 1.72 (1.19, 2.49)                      |             |
| Low-dose aspirin                            | 0.76 (0.64, 0.90)               | 0.47 (0.33, 0.67)     | 0.77 (0.68, 0.88)                 | 0.71 (0.62, 0.82)  | 0.65 (0.60, 0.70)        |                                          |             |
| White blood cells >11,000/μl                |                                 |                      |                                 |                  |                        | 1.35 (1.16, 1.56)                      |             |
| Creatinine >1.2 mg/dl                       | 1.20 (1.00, 1.44)               |                      |                                 |                  |                        |                                          |             |
| Hematocrit ≤38%                             | 1.21 (1.04, 1.42)               |                      |                                 |                  |                        | 1.47 (1.36, 1.58)                      |             |
| Serum sodium >145 mM                        | 1.64 (1.07, 2.52)               |                      |                                 |                  |                        |                                          |             |

Michaud et al. Arthritis Research & Therapy 2013, 15:R195
http://arthritis-research.com/content/15/6/R195
Table 3 Multivariable logistic-regression model results for complications associated with hip or knee TJA\textsuperscript{a} (Continued)

|                          | GCS (30 days) | GCS (6 months) | GCS (1 year) | GCS (VASQIP) | Constant |
|--------------------------|---------------|----------------|--------------|--------------|----------|
| GCS (30 days)            | 0.75 (0.58, 0.96) | 0.82 (0.69, 0.97) |              |              |          |
| GCS (6 months)           |               | 1.86 (1.33, 2.60) |              |              |          |
| GCS (1 year)             |               |                | 0.45 (0.18, 0.72) |              |          |
| GCS (VASQIP)             |               |                |              | 1.52 (1.26, 1.82) |          |
| Constant                 |               |                |              |              | 557.9    |

\textsuperscript{a}Except where noted, odds ratios (95% CI).
\textsuperscript{b}Cox proportional hazards regression, hazard ratios (95% CI).
\textsuperscript{c}Variable was forced into all models.
\textsuperscript{d}Not significant and removed for not meeting proportional hazard requirement.

CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; GCS, glucocorticosteroid; OA, osteoarthritis; RA, rheumatoid arthritis; TIA, transient ischemic attack. TJA, total joint arthroplasty.
postoperative infections, which were protective when used less than 30 days before surgery (OR, 0.75 (0.58 to 0.96)), and deep-wound infections, which were associated with GCS when dispensed less than 6 months beforehand (1.86 (1.33 to 2.60)). It is difficult to interpret this without access to dosage of GCS, but it is likely that a bias exists for near-TJA surgical date prescription compared with longer-term prescriptions, which have been shown to have a near-exponential dose-time impact on future infections [29].

The systematic review by Singh and colleagues [10] addressed mortality after TKA and THA. They found no significant difference in 30-day and 90-day mortality between RA and OA patients, although they indicated that this may be due to the small number of studies reporting these data (for example, a total of four deaths in 481 RA patients at 90 days). We suspect that all 20 of their reported 30-day mortality events (of 7,174 RA patients) came from one surgical site during 1969 through 1997 [13,15], all before the dates of the current study. Similar power issues are found with the Ravi et al. [18] systematic review that showed no difference in mortality.

Domsic et al. [30] looked at mortality during the hospital stay for TKA and THA by using the large Nationwide Inpatient Sample from 1993 through 2006. They reported similar results that mortality in RA was no different from that in their non-lupus and non-RA controls, although in several multivariable subanalyses, they found RA to be protective of mortality for all elective surgeries: OR, 0.58 (95% CI, 0.41 to 0.82), and for all TKA, OR, 0.64 (0.44 to 0.92). The reasons for these findings are not clear, although their average length of hospital stay was 2 to 3 days shorter than ours, and they had a greater RA versus OA age difference.

A limitation of our study is the relatively low ratio of RA to OA patients (2.4%), which reduced our power to detect less-robust associations, although this is likely related to the substantially increased number of men in the VA system, compared with the average clinical population, who are less likely than women to develop RA. Recognizing these limitations, our study results are still based on a considerable number of surgeries, making it one of the largest studies of its kind to date. Although important RA covariates of clinical disease activity were not available, our study did include the possible impact of RA treatments like GCS, along with comorbidities that are often associated with worse disease and infections [29]. Our data unfortunately did not record the reason for a return to the operating room, and we must speculate whether this was due to dislocations or other causes.

This highlights another limitation, that our study relies on the patient diagnosis and classification of a large registry and that we were unable to validate the reported outcomes or review the patient records, although this is true of almost all administrative data studies.

The important risk factor of obesity was not available in our data. The study by Suleiman et al. [31] did not find any increased rates of perioperative complications related to obesity in patients undergoing TKA and THA, although they did not investigate by arthritis diagnosis. With RA, we found an expected increase in TJA and co-morbidity with obesity, although we also found increased TJA in those who were underweight and a decrease in mortality in those who were overweight [32]. A similar protective effect of obesity was found, even after taking RA diagnosis into account in the Clement et al. study of mortality after TKA [9], although by keeping body mass index a continuous measure, they were unable to indicate whether this was driven by those who were underweight.
A similar issue may have occurred in the Olmsted County study that found only an increase in TJA with obesity [8].

Conclusions
Although we expected to find greater risk of complications in RA patients, especially because TJA is reserved for those with the most-severe disease and therefore greater risk, our results did not support this in the short term. Although preoperative risk assessment remains critical in mitigating postoperative complication, including infection and cardiovascular events, our results would suggest that the diagnosis of RA alone should not preclude consideration of this important intervention. Future studies are needed to elucidate the impact of specific treatments, obesity, and any additional steps surgeons may take with RA patients around these increasingly important surgical procedures.

Additional file

Additional file 1: Table S1. Excluded laboratory characteristics of VA VASQIP patients receiving TKA or THA by OA or RA diagnosis.

Abbreviations
ASA: American Society of Anesthesiologists; BIRLS: Beneficiary Identification and Services Locator System; CCH: Congestive heart failure; COPD: Chronic obstructive pulmonary disease; CPR: Cardiopulmonary resuscitation; CPT: Current procedural terminology; CV: Cardiovascular; CVA: Cerebrovascular accident; DMARD: Disease-modifying antirheumatic drug; GCS: Glucocorticosteroid; HR: Hazard ratio; ICD9: International Statistical Classification of Disease and Related Health Problems, Ninth Revision; OA: Osteoarthritis; OR: Odds ratio; PBM: Pharmacy Benefits Management; PO: Postoperative; RA: Rheumatoid arthritis; SD: Standard deviation; SGOT: Serum glutamic oxaloacetic transaminase; THA: Total hip arthroplasty; TIA: Transient ischemic attack; TJA: Total joint arthroplasty; TKA: Total knee arthroplasty; VA: Veterans Affairs; VASQIP: Veterans Affairs Surgical Quality Improvement Program.

Competing interests
EF receives royalties for the development of shoulder prostheses. The remaining authors declare that they have no competing interests.

Authors’ contributions
TM and JO acquired the data. KM and TM conceived and designed the study. EF and KG contributed to interpretation of the data. All authors contributed to, edited, read, and approved the final manuscript.

Acknowledgements
The authors thank Harlan Sayles for his valuable statistical review. The authors also acknowledge the VA Surgical Quality Data Use Group (SQDUG) for its role as scientific advisors and for the critical review of data use and analysis presented in this manuscript. This study was funded by the Nebraska Arthritis Outcomes Research Center. Dr. Michaud received additional support from the Arthritis Foundation’s New Investigator Award. The opinions expressed are those of the authors and not necessarily those of the Department of Veterans Affairs or the United States Government.

Author details
1Omaha Veterans Affairs Medical Center, Omaha, Nebraska 68198-6270, USA.
2National Data Bank for Rheumatic Diseases, Wichita, Kansas 67218-6270, USA.
3University of Nebraska Medical Center, Omaha, NE 68198-6270, USA.
4University of Nebraska Medical Center, 986270 Nebraska Medical Center, Omaha, NE 68198-6270, USA.

Received: 10 May 2013 Accepted: 7 November 2013
Published: 20 November 2013

References
1. Centers for Disease Control National Center for Health Statistics. FastStats: inpatient surgery. [http://www.cdc.gov/nchs/fastats/insurg.htm].
2. Kane RL, Saleh KJ, Wilt TJ, Benhadsy B, III WW, MacDonald RM, Rutks I. Total Knee Replacement. Evidence Report/Technology Assessment No. 86 (Prepared by Minnesota Evidence-based Practice Center, Minneapolis, Minnesota). AHRQ Publication No 04-E006-1. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
3. Kurtz SM, Ong KL, Schmier J, Mowaf F, Saleh K, Dybbvik E, Kanholm J, Gaeckell G, Havelin LI, Furnes O, et al: Future clinical and economic impact of revision total hip and knee arthroplasty. J Bone Joint Surg Am 2007, 89:144–151.
4. Helmcig CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremer HM, Mayes MD, Merkel PA, et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008, 58:15–25.
5. Kurtz S, Mowaf F, Ong K, Chan N, Lau E, Halpern M: Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am 2005, 87:1487–1497.
6. Cram P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR: Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991–2010. JAMA 2012, 308:1227–1236.
7. Kurtz S, Ong K, Lau E, Mowaf F, Halpern M: Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007, 89:780–785.
8. Shout CA, Crowson CS, Gabriel SE, Matteson EL: Orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population-based study focused on surgery rates, sex, and mortality. J Rheumatol 2012, 39:491–498.
9. Clement ND, Jenkins PJ, Benkelj U, Walmoby P: Predictors of mortality after total knee replacement: a ten-year survivorship analysis. J Bone Joint Surg Br 2012, 94:200–204.
10. Singh JA, Kudukulam J, Riddle DL, Strand V, Tugwell P: Early postoperative mortality following joint arthroplasty: a systematic review. J Rheumatol 2011, 38:1507–1515.
11. Robertson O, Stefandottir A, Lindgren L, Ranstam J: Increased long-term mortality in patients less than 55 years old who have undergone knee replacement for osteoarthritis: results from the Swedish Knee Arthroplasty Register. J Bone Joint Surg Br 2007, 89:599–603.
12. Gill GS, Mills D, Joshi AB: Mortality following primary total knee arthroplasty. J Bone Joint Surg Am 2003, 85-A:452–453.
13. Parvizi J, Sullivan TA, Trousdale RT, Lewallen DG: Thirty-day mortality after total knee arthroplasty. J Bone Joint Surg Am 2003, 85-A:1157–1161.
14. Dearborn JT, Harris WH: Postoperative mortality after total hip arthroplasty: an analysis of deaths after two thousand seven hundred and thirty-six procedures. J Bone Joint Surg Am 1998, 80:1291–1294.
15. Parvizi J, Johnson BG, Rowland C, Ereh MH, Lewallen DG: Thirty-day mortality after elective total hip arthroplasty. J Bone Joint Surg Am 2001, 83-A:1524–1528.
16. Louie GH, Ward MW: Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis 2010, 69:868–871.
17. Wolfe F, Zwillch SH: The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:1072–1082.
18. Ravi B, Escott B, Shah PS, Jenkinson R, Chahal J, Bogoch E, Kreder H, Hawker G: A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum 2012, 64:3839–3849.
19. Weaver F, Hynes D, Dockinson W, Wixon R, Khi, S, Daley J, Henderson WG: Preoperative risks and outcomes of hip and knee arthroplasty in the Veterans Health Administration. J Arthroplasty 2003, 18:693–708.
20. Radcliffe TA, Henderson WG, Stoner TJ, Khuri SF, Dohm M, Hutt E: Patient risk factors, operative care, and outcomes among older community-dwelling male veterans with hip fracture. J Bone Joint Surg Am 2008, 90:34–42.
21. Davis CL, Pierce JR, Henderson W, Spencer CD, Tyler C, Langberg R, Swafford J, Felan GS, Keams MA, Booker B: Assessment of the reliability of data collected for the Department of Veterans Affairs national surgical quality improvement program. J Am Coll Surg 2007, 204:550–560.

22. Khuri SF, Daley J, Henderson W, Hur K, Demakis J, Aust JB, Chong V, Fabri PJ, Gibbs JD, Grover F, et al: The Department of Veterans Affairs’ NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care: National VA Surgical Quality Improvement Program. Ann Surg 1998, 228:991–507.

23. Singh JA, Holmgren AR, Noorbaloochi S: Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004, 51:952–957.

24. Bradley KA, Rubinsky AD, Sun H, Byson CL, Bishop MJ, Blough DK, Henderson WG, Maynard C, Hawn MT, Tonnesen H, et al: Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med 2011, 26:162–169.

25. Fehring TN, Mikuls TR, Michaud KD, Henderson WG, O’Dell JR: Shoulder arthroplasties have fewer complications than hip or knee arthroplasties in US veterans. Clin Orthop Relat Res 2010, 468:717–722.

26. Weiss RJ, Stark A, Wick MC, Ehlin A, Palmblad K, Wretenberg P: Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis 2006, 65:325–341.

27. Jamsen E, Huhtala H, Puolakka T, Moilanen T: Risk factors for infection after knee arthroplasty: a register-based analysis of 43,149 cases. J Bone Joint Surg Am 2009, 91:38–47.

28. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, Hassen AD, Matteson EL: Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:1713–1720.

29. Dixon WG, Abrahambowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suisa S, Sylvestre MP: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 2012, 71:128–133.

30. Domsic RT, Lingala B, Krishnan E: Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol 2010, 37:1467–1472.

31. Suileiman LJ, Otegna G, Onyut SK, Gonzalez DO, Tran DO, Onyike A, Turner PL, Fullum TM: Does BMI affect perioperative complications following total knee and hip arthroplasty? J Surg Res 2012, 174:7–11.

32. Wolfe F, Michaud K: Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:1471–1479.

doi:10.1186/ar4385
Cite this article as: Michaud et al.: Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. Arthritis Research & Therapy 2013 15:R195.